People · Operator
Named in public records as an officer, director or promoter · active 2008–2019 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Orexigen Therapeutics, Inc. | — | Pharmaceuticals | Series D+ | $274.6M | $1.8B | 2015 |
| Hyperion Therapeutics Inc | — | Pharmaceuticals | Series B | $67.9M | $271.7M | 2014 |
| Ikaria Holdings Inc | — | Pharmaceuticals | Series C | $54.9M | $1.9B | 2008 |
| Inovio Pharmaceuticals, Inc. | — | Biotechnology | Series B | $19.2M | $160.4M | 2019 |
Lota S Zoth at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Lota S Zoth on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| James Healy | 1 | 8 |
| James I. Healy | 1 | 7 |
| Brian H. Dovey | 1 | 7 |
| Louis C. Bock | 1 | 7 |
| Thomas Lynch | 1 | 7 |
| Rob Hopfner | 1 | 6 |
| Bryan E. Roberts | 1 | 6 |
| Jake Nunn | 1 | 5 |
| Bijan Salehizadeh | 1 | 5 |
| DAVID E. SHAW | 1 | 5 |
| Daniel Perez | 1 | 5 |
| Robert T. Nelsen | 1 | 5 |
| Donald Santel | 1 | 4 |
| Jake R. Nunn | 1 | 4 |
| Gaurav Aggarwal | 1 | 3 |
| DAVID GRYSKA | 1 | 3 |
| Randy H. Thurman | 1 | 3 |
| Wendy L Yarno | 1 | 3 |
| Robert Hopfner | 1 | 3 |
| Matthew M. Bennett | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.